

## Message Text

LIMITED OFFICIAL USE

PAGE 01 STATE 024190  
ORIGIN NEA-10

INFO OCT-01 AS-01 ISO-00 EB-08 COME-00 /020 R

DRAFTED BY NEA/INS:JRGRAHAME:JES

APPROVED BY NEA/INS:DKUX

EB/IFD/OSB:RBUCK (INFO)

-----030837Z 033098 /11

R 030029Z FEB 77

FM SECSTATE WASHDC

TO AMEMBASSY NEW DELHI

LIMITED OFFICIAL USE STATE 024190

E.O. 11652: N/A

TAGS: USINJC, EINV, IN, US

SUBJECT: PHARMACEUTICALS

REF: NEW DELHI 1301

1. WE HAVE PROVIDED INFORMATION CONTAINED REFTEL TO PMA. ALTHOUGH PMA MEETING HAS BEEN RESCHEDULED FOR FEB 8, WIEN, FAR EAST GROUP CHAIRMAN, HAS ALREADY DISCUSSED THIS DEVELOPMENT WITH SEVERAL MEMBERS. INITIAL REACTIONS WERE THAT THIS DECISION WAS AN ENCOURAGING AND POSITIVE DEVELOPMENT AND MET THE BASIC PMA WISH THAT THE FERA BE APPLIED TO FOREIGN DRUG FIRMS. WE EXPECT TO HAVE DETAILED PMA COMMENT NEXT WEEK.

2. WE AND PMA WOULD BE INTERESTED IN RECEIVING FERNANDEZ'S COMMENTS WHEN YOU CAN GET THEM.  
VANCE

LIMITED OFFICIAL USE

NNN

## Message Attributes

**Automatic Decaptioning:** X  
**Capture Date:** 01-Jan-1994 12:00:00 am  
**Channel Indicators:** n/a  
**Current Classification:** UNCLASSIFIED  
**Concepts:** DRUG INDUSTRY  
**Control Number:** n/a  
**Copy:** SINGLE  
**Sent Date:** 03-Feb-1977 12:00:00 am  
**Decaption Date:** 01-Jan-1960 12:00:00 am  
**Decaption Note:**  
**Disposition Action:** RELEASED  
**Disposition Approved on Date:**  
**Disposition Case Number:** n/a  
**Disposition Comment:** 25 YEAR REVIEW  
**Disposition Date:** 22 May 2009  
**Disposition Event:**  
**Disposition History:** n/a  
**Disposition Reason:**  
**Disposition Remarks:**  
**Document Number:** 1977STATE024190  
**Document Source:** CORE  
**Document Unique ID:** 00  
**Drafter:** JRGRAHAME:JES  
**Enclosure:** n/a  
**Executive Order:** N/A  
**Errors:** N/A  
**Expiration:**  
**Film Number:** D770038-0851  
**Format:** TEL  
**From:** STATE  
**Handling Restrictions:** n/a  
**Image Path:**  
**ISecure:** 1  
**Legacy Key:** link1977/newtext/t19770276/aaaacpdz.tel  
**Line Count:** 46  
**Litigation Code IDs:**  
**Litigation Codes:**  
**Litigation History:**  
**Locator:** TEXT ON-LINE, ON MICROFILM  
**Message ID:** 1ec332cc-c288-dd11-92da-001cc4696bcc  
**Office:** ORIGIN NEA  
**Original Classification:** LIMITED OFFICIAL USE  
**Original Handling Restrictions:** n/a  
**Original Previous Classification:** n/a  
**Original Previous Handling Restrictions:** n/a  
**Page Count:** 1  
**Previous Channel Indicators:** n/a  
**Previous Classification:** LIMITED OFFICIAL USE  
**Previous Handling Restrictions:** n/a  
**Reference:** 77 NEW DELHI 1301  
**Retention:** 0  
**Review Action:** RELEASED, APPROVED  
**Review Content Flags:**  
**Review Date:** 08-Mar-2005 12:00:00 am  
**Review Event:**  
**Review Exemptions:** n/a  
**Review Media Identifier:**  
**Review Release Date:** n/a  
**Review Release Event:** n/a  
**Review Transfer Date:**  
**Review Withdrawn Fields:** n/a  
**SAS ID:** 3416437  
**Secure:** OPEN  
**Status:** NATIVE  
**Subject:** PHARMACEUTICALS  
**TAGS:** EINV, IN, US, USINJC  
**To:** NEW DELHI  
**Type:** TE  
**vdkgvwkey:** odb://SAS/SAS.dbo.SAS\_Docs/1ec332cc-c288-dd11-92da-001cc4696bcc  
**Review Markings:**  
Margaret P. Grafeld  
Declassified/Released  
US Department of State  
EO Systematic Review  
22 May 2009  
**Markings:** Margaret P. Grafeld Declassified/Released US Department of State EO Systematic Review 22 May 2009